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Dr Craig R. Smith (New York, NY). My disclosure is I am the
surgical principal investigator for the PARTNER trial.
The authors are to be congratulated for demonstrating remark-
ably low mortality in octogenarians who are undergoing conven-
tional surgical AVR. The most important implication of these
findings is that transcatheter techniques should not be extended to
lower-risk patients using age alone as a marker for elevated risk,
which is a critical consideration in trial design and in labeling as
these devices come out. So I think that is an important contribution.
First, I have a comment and a question. My comment first.
I must respectfully object to the implication that MiniAVR as op-
posed to any other kind deserves partial credit for these excellent
mortality results. It would be equally relevant to title this article
‘‘AVR in octogenarians done by varsity surgeons from Boston.’’
Numerous retrospectively matched studies to the contrary notwith-
standing, there is no randomized controlled evidence that a Mini-
AVR reduces mortality, there just isn’t. Variables such as intensive
care unit stay, length of time to discharge, and so forth have been
shown, and although probably innocently, they are easily manipu-
lated by enthusiasts.
Now, how could this be so? I will remind you of the famous in-
ternal thoracic artery study, internal thoracic artery ligation, in
which when restratified according to whether the surgeon was an
enthusiast or a skeptic, the enthusiast’s patients had 40% greater
relief of angina. So the surgeon is a powerful placebo. So when
you are not talking about mortality, very powerful effects. In
a more recent study from the University of Cologne, when subjects
were told they were given a ‘‘lucky’’ ball to putt with that had been
very successful in other people’s hands, they sank 35%more putts.
So I think we should be aware of this and remember that patients
and referring physicians are listening, and embellishing these out-
standing results with a link to a favorite technical trademark only
moves that audience from ignorance to superstition.
Now tomyquestion. I think you are right to be proud of achieving
3% operative mortality in a cohort reported to have an STS score of
14%. This does concern me a little bit for several reasons. I would
love to think that this is a benchmark for the TAVI procedure, as
you suggest, but I do have some concerns. According to the
methods, you included everyone aged more than 80 years having
this procedure. As you probably know, in both the New York State
database and the STS database, an STS score of 14 represents well
less than 5% of the population. Age more than 80 years adds less
than 3% to the STS score. So I have towonder, where did those extra
11 points come from? I don’t think that 10%with renal failurewould
do it, although I could be wrong. Many 90-year-olds have STS
scores less than 10. There is a series from Northwestern this year,
190 patients, who seem to be just as unselected as this cohort, in
which the average STS score in those agedmore than 80 years, there
were 41 of them, was 6. Their operative mortality was 2.4%, similar
to what you reported here. In the operable cohort of the PARTNER
trial, with an average age of 83 years, the STS score is 11.8, similar
to the 12% in the Leipzig series you heard this morning. And any
center that has been involved in this sort of thing knows that that334 The Journal of Thoracic and Cardiovascular Surgquickly eliminates the majority of conventional AVR candidates.
So I will say again, age more than 80 years adds less than 3% to
the risk score. Now, in aggregate, these observations make an aver-
age STS score of 14 extremely surprising for the cohort presented,
selected only by age. So how do you explain an average STS score
that seems impossibly high in this unselected group?
Dr ElBardissi. That is a great question. Thank you, Dr Smith. It
would be difficult for me to go through the details and identify
every factor and how that contributed to the STS score of 14%.
I will say that 20% of our patients had reoperations, and, as you
mentioned, 10% of patients had renal failure. This was a particu-
larly sick cohort of patients, and although I would love to have
how every factor contributed to that mean score, I just don’t
have that information right now.
Dr Smith. I wouldn’t expect you to.
Dr Robert J. Cusimano (Toronto, Ontario, Canada). Along
the lines of the other one, whenever we look at someone for a trans-
catheter valve, a lot of the times there is a calcified aorta and some-
times there is this word frailty; the reason we accept them is
because of frailty. How have you been able to tease the frailty
part of the whole thing, and the second question is, how many of
your patients had calcified aortas and what do you do with those
patients?
Dr ElBardissi. I think it is important to note that our institution
is also participating in the PARTNER trial. So this is not meant to
be a presentation saying everyone should have an open AVR.
I think what you are identifying is what a number of studies
have identified, which is there are a number of factors that aren’t
included in the STS score, such as patient frailty, porcelain aorta,
severe liver failure, which generally are thought to contribute sig-
nificantly to patient mortality, but, again, are not included in the
STS score.
Patients who have a completely calcified aorta not amenable at
all to cancellation are those whom we would generally refer and
include in the PARTNER trial. These are highly select patients.
These are obviously patients who underwent the scrutiny of sur-
geons and cardiologists and were deemed to be operative candi-
dates for surgical AVR. So you can probably say that these are
relatively healthy high-risk patients.
Dr Thoralf Sundt (Rochester, Minn). I appreciate that the in-
tent of this presentation is really more to compare surgical AVR
with percutaneous AVR, but, predictably, my question, much
like Craig’s, relates to the value of the ‘‘mini’’ component of
this. If I understand correctly, you have sacrificed antegrade perfu-
sion for femoral artery perfusion to gain 3 inches of sternum, and
you have a fair number of strokes. Can you tell me anything about
those strokes and make me feel better about pumping these people
from the groin? These folks are 80 years old, and a lot of them have
a lot of calcium in their descending thoracic aortas.
DrElBardissi. I can tell you that 4% of our patients had strokes,
and I reviewed all these strokes. The majority of those were small
strokes the patient recovered from. There were a couple that were
pretty significant strokes. I still don’t think a 4% stroke rate in this
cohort of patients, though, is really that significant and should de-
ter someone from providing patients with a long-lasting AVR
when they may very well make it through the postoperative phase
with no complications. In fact, they would be likely to get through
the postoperative phase with no complications.ery c February 2011
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Moon CommentaryDr Sundt. And I agree with you. I didn’t mean to take a shot at
you for the 4% rate in the primary cases or the 8% in the redos. The
real question, though, is, would the stroke rate have been less if
they had been perfused from the ascending aorta rather than
from the groin? But I appreciate that it is difficult to answer that
question.
Dr Bolman. Well, they are perfused antegrade. The patients
receive percutaneous venous but central aortic cannulation.
Dr Sundt. It was only percutaneous femoral?
Dr ElBardissi. They are cannulated centrally and perfused cen-
trally except in reoperations, in which case they are perfused pe-
ripherally through the femoral artery or they are perfused
through the axillary artery, but in all primary operations they are
perfused through the aorta.
Dr Sundt. I am sorry I misunderstood. Thank you very much.
Dr Hillel Laks (Los Angeles, Calif). One of the factors that was
not discussed in the article on robotic mitral valve surgery that we
just heard or in this article on MiniAVRwas the effects of these ap-
proaches on the brain, on neurocognitive function. One of the great
concerns that many surgeons have is the issue of de-airing of the
heart at the end of these procedures, which has been shown by
transcranial Doppler to shower the brain with microemboli, andCOMMEN
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The Journal of Thoracic and Cathe literature is replete with studies retrospectively that have shown
30% of patients having some neurocognitive dysfunctions. Do you
know of any studies that have been done to compare these ap-
proaches, and particularly this one, in terms of neurocognitive func-
tion recovery, which is particularly pertinent to the old age group?
Dr ElBardissi.As far as neurocognitive function, if we are talk-
ing about these transient, diffuse neurocognitive dysfunction epi-
sodes, I don’t know of any studies. If we are talking about acute
events such as strokes or transient ischemic attacks, I can tell
you that our institution did a retrospective study that was published
in the Annals of Surgery and found no significant difference be-
tween the minimally invasive approach and the open approach
as far as those acute events are concerned.
Dr Laks. I would like to emphasize that the incidence of clin-
ically apparent strokes underrepresents diffuse brain injury that
can result in neurocognitive dysfunction and that can be present
as long as 6 months after surgery, and it is thought that many of
those may be permanent. I think before we declare that these
approaches are superior or equal, a randomized or equivalent
type of study needs to be done looking at neurocognitive function
both for robotic mitral valve surgery and for other minimally
invasive approaches.TARYPredictive value of surgical scoring systems in determining operative
risk for octogenarians undergoing aortic valve replacementMarc R. Moon, MDIn a retrospective, single-center study, ElBardissi and asso-
ciates1 report the results of isolated aortic valve replacement
(AVR) in 249 octogenarians from 1996 to 2009, during which
time they performed a minimally invasive approach in almost
all patients. This study does not compare the minimally
invasive approach with the traditional AVR via median ster-
notomy, so any conclusions as to the impact of a particular
surgical approach would not be reasonable. Therefore, I will
make no reference to the specific surgical technique, but referonly to AVR in general. The authors’ specific aims included
the following: (1) demonstrate that AVR can be performed
safely in high-risk patients; (2) document long-term survival
as a benchmark for future studies; and (3) assess the reliability
of two current risk-prediction models, The Society of
Thoracic Surgeons Predicted Risk of Mortality (STS-
PROM)andmodifiedEuropeanSystemforCardiacOperative
Risk Evaluation (EuroSCORE) algorithms,2,3 hypothesizing
that these current risk-prediction models ‘‘overestimate risk
in appropriately chosen and optimized patients.’’ Although
the authors were successful in addressing specific aims 1
and 2, they may have fallen short in their assessment of the
STS-PROM and EuroSCORE risk score algorithms.SPECIFIC AIM 1
The authors report operative mortality of 3% 2% (95%
confidence limit) for octogenarians undergoing AVR during
this modern era. Mean ventilator duration was 16  27rdiovascular Surgery c Volume 141, Number 2 335
